CONCLUSION:
MIS-N is no longer a hypothesis, but an actual disease entity with multiple reports available in literature. This disease is ever-evolving with widening scope of symptomatology. Thromboembolic complications secondary to inflammatory response after SARS-CoV2 exposure should be considered in infants and children. It is essential for the neonatologists to consider the possibility of MIS-N in neonates with in-utero exposure for early diagnosis and management as well as share the data for better understanding of the disease and framing the best treatment practices. Diagnostic criteria and management strategies for MIS-N as well as thromboembolism in MIS-N should be developed, distinct from those currently available for children.